mw03, you're right mate. IGF-1 is being tested because it is already approved by the FDA for growth related conditions. It is definitely a competitor.
There are a couple of reasons why nnz-2566 walks all over IGF-1 though.
1. nnz-2566 is orally available while IGF-1 requires injections.
2. IGF-1 cannot be used with older patients in all diseases as it will promote excessive growth, while nnz-2566 does not have that issue.
NEU Price at posting:
12.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)